Categories

Teligent Pharma, Inc.’s Issues Worldwide Voluntary Recall of Lidocaine HCl Topical Solution USP 4% Due to Super Potency

Buena, NJ, Teligent Pharma, Inc. is voluntarily recalling two lots of Lidocaine HCl Topical Solution USP 4%, 50ml in a screw cap glass bottle listed in the table below to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specif

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teligent-pharma-incs-issues-worldwide-voluntary-recall-lidocaine-hcl-topical-solution-usp-4-due

 
Categories

Comisión de Vacunación reafirma importancia de que mujeres embarazadas se vacunen contra COVID-19

Comisión de Vacunación reafirma importancia de que mujeres embarazadas se vacunen contra COVID-19

Comisión de Vacunación reafirma importancia de que mujeres embarazadas se vacunen contra COVID-193 de diciembre del 2021. La Comisión Nacional de Vacunación y Epidemiología (CNVE) reiteró la importancia de la inmunización contra COVID-19

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2225-comision-de-vacunacion-reafirma-importancia-de-que-mujeres-embarazadas-se-vacunen-contra-covid-19

 
Categories

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia3 de diciembre del 2021. La Comisión Nacional de Vacunación y Epidemiología (CNVE) aprobó que a partir del miércoles 8 de diciembre se proceda

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2224-tercera-dosis-covid-19-comenzara-a-aplicarse-en-centros-de-larga-estancia

 
Categories

Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 – Letter to Clinical Laboratory Staff and Health Care Providers

Laboratories should expect some false negative results because the SARS-CoV-2 virus can mutate over time and not be detected.

http://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2

 
Categories

Gilead Issues A Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates

Foster City, CA, Gilead Sciences Inc. (Nasdaq: GILD) today announced it is voluntarily recalling two lots of Veklury® (remdesivir 100 mg for injection) to the user level. Gilead Sciences Inc. received a customer complaint, confirmed by the firm’s investigation, of the presence of glass particulates.

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-two-lots-vekluryr-remdesivir-due-presence-glass

 
Categories

August 7, 2019 UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality

The FDA is providing updated information about a late mortality signal in patients treated for peripheral artery disease (PAD) in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents. This communication updates the January 17 and March 15, 2019 notifications.

http://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel

 
Categories

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injectio

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-one-lot-enoxaparin-sodium-injection-usp-40mg04-ml-due